Impax Laboratories, Inc.
http://www.impaxlabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Impax Laboratories, Inc.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act
Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.
US Senate Advances BIOSECURE Legislation As China Biotech Security Heats Up
The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.
US Draft Bill Highlights Perceived China Biotech Threat
A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- CorePharma LLC
- Impax Generics
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice